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Differences and Similarities in the Clinicopathological
Features of Pancreatic Neuroendocrine Tumors in China
and the United States
A Multicenter Study
Li-Ming Zhu, MD, Laura Tang, MD, PhD, Xin-Wei Qiao, MD, Edward Wolin, MD,
Nicholas N. Nissen, MD, Deepti Dhall, MD, Jie Chen, MD, Lin Shen, MD, Yihebali Chi, MD,
Yao-Zong Yuan, MD, Qi-Wen Ben, MD, Bin Lv, MD, Ya-Ru Zhou, MD, Chun-Mei Bai, MD,
Jie Chen, MD, Yu-Li Song, MD, Tian-Tian Song, MD, Chong-Mei Lu, MD, Run Yu, MD, PhD,
and Yuan-Jia Chen, MD
Abstract: The presentation, pathology, and prognosis of pancreatic
neuroendocrine tumors (PNETs) in Asian patients have not been
studied in large cohorts. We hypothesized that the clinicopathological
features of PNETs of Chinese patients might be different from those of
US patients. The objectives of this study were to address whether
PNETs in Chinese patients exhibit unique clinicopathological features
and natural history, and can be graded and staged using the WHO/
ENETS criteria.
This is a retrospective review of medical records of patients with
PNETs in multiple academic medical centers in China (7) and the
United States (2). Tumor grading and staging were based on WHO/
ENETS criteria. The clinicopathological features of PNETs of Chinese
and US patients were compared. Univariate and multivariate analyses
were performed to find associations between survival and patient
demographics, tumor grade and stage, and other clinicopathological
characteristics.
A total of 977 (527 Chinese and 450 US) patients with PNETs were
studied. In general, Chinese patients were younger than US patients
(median age 46 vs 56 years). In Chinese patients, insulinomas were the
most common (52.2%), followed by nonfunctional tumors (39.7%),
whereas the order was reversed in US patients. Tumor grade distribution
was similar in the 2 countries (G1: 57.5% vs 55.0%; G2: 38.5% vs
41.3%; and G3: 4.0% vs 3.7%). However, age, primary tumor size,
primary tumor location, grade, and stage of subtypes of PNETs were
significantly different between the 2 countries. The Chinese nonfunc-
tional tumors were significantly larger than US ones (median size 4 vs
3 cm) and more frequently located in the head/neck region (54.9% vs
34.8%). The Chinese and US insulinomas were similar in size (median
1.5 cm) but the Chinese insulinomas relatively more frequently located
in the head/neck region (48.3% vs 26.1%). Higher grade, advanced
stage, metastasis, and larger primary tumor size were significantly
associated with unfavorable survival in both countries.
Several clinicopathological differences are found between Chinese
and US PNETs but the PNETs of both countries follow a similar natural
history. The WHO tumor grading and ENETS staging criteria are
applicable to both Chinese and US patients.
(Medicine 95(7):e2836)
Abbreviations: DFS = disease-free survival, NF = nonfunctional
PNET, OS = overall survival, PNET = pancreatic neuroendocrine
tumor.
INTRODUCTION
P ancreatic neuroendocrine tumors (PNETs) are a group ofuncommon tumors arising in the endocrine pancreas but the
incidence of these tumors has increased worldwide.1–6 They are
classified into subgroups accordingly to various criteria.1,2,5
Based on whether they cause clinical hormonal excess syn-
dromes, the PNETs are classified as functional or nonfunc-
tional. Using proliferative markers, PNETs are categorized as
low-, intermediate-, or high-grade.7–9 Using the TNM (tumor,
node, and metastasis) system, PNETs are divided into 4 stages
of tumor advancement.8–10 PNETs grade and stage are the
major determinants of prognosis.10
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The above tumor taxonomy has largely been based on
PNETs in European and US patients. PNETs are well known in
Asian countries although the epidemiology is not clearly
characterized.6,11–16 There have not been large studies of
PNETs in Asian patients. The presentation, pathology, and
prognosis of PNETs in Asian patients are not clearly described
due to the limited number of patients in existing studies. It is not
known whether PNETs in Asian patients exhibit unique natural
history or can be graded and staged using available criteria.
Themost populous and third largest country,China probably
has the greatest PNET burden per country.11–14 We thus retro-
spectively compared the presentation, pathology, and prognosis
of PNETs in Chinese and US patients in a multicenter study.
METHODS
Data Retrieval
A total of 977 patients with histological diagnosis of PNETs
from 1983 to 2012 at each participating hospital were studied;
these included 344 patients from Peking Union Medical College
Hospital, 32 from Cancer Institute and Hospital of Chinese
Academy ofMedical Sciences, 24 fromBeijing Cancer Hospital,
all in Beijing, 7 from the Third Hospital of Hebei Medical
University, Shijiazhuang, Hebei Province, all in the north of
China; 60 from the First Affiliated Hospital of Sun Yat-Sen
University, Guangzhou, Guangdong Province, 54 from Ruijin
Hospital of Shanghai Jiao Tong University, Shanghai, 6 from the
First AffiliatedHospital of Zhejiang ChineseMedical University,
Hangzhou, Zhejiang Province, all in the south of China; 342 from
Memorial Sloan Kettering Cancer Center, New York, and 108
from Cedars-Sinai Medical Center, Los Angeles, both in United
States. The patients’ electronic or paper medical records were
reviewed and clinical history, laboratory test results, imaging
studies, and pathological reports were analyzed and extracted.
This study has been approved by the Institutional Review Board
of the respective participating centers.
Diagnosis and Treatment
The diagnosis and management approaches were dictated
by the local standards but were mostly similar.11–14 Briefly,
diagnosis of PNETs was suspected if the patients exhibited a
hormonal excess syndrome and imaging identified pancreatic or
liver masses, or the patients had pancreatic or liver masses either
incidentally discovered or found during the workup of abdomi-
nal symptoms. In either case, biopsy of the pancreatic mass or
liver lesions was done to establish the diagnosis of PNETs. For
treatment, the pancreatic PNET and liver metastatic lesions
were resected whenever possible, followed by locoregional
therapy of residual liver lesions and systemic therapy composed
of a somatostatin analog and other medications. Additional
therapy was dictated by the treating physicians and
by availability.
Pathological Classification
Tumor grading and staging were performed based on the
ENETS criteria.9,10 For grading, both mitotic index and Ki-67
labeling were measured; when the results were discordant, the
higher grade assigned by either was defined as the grade of the
tumor. For staging, the TNM system was used.
Statistical Analysis
Student t test, x-test or Fisher exact test, and Mann–
Whitney method were used. Logistic regression was used for
multivariate analysis. Survival of patients was analyzed by the
Kaplan–Meier method and Cox proportional hazard model.
Two-tailed test was used in all statistical analyses. P 0.05 was
considered significant.
RESULTS
General Description of PNETs
PNET Presentation
Four of the 7 Chinese centers locate in Northern part of
China, and 3 in Southern China, respectively. The 2 US centers
locate in the East and West Coast of the United States, respect-
ively. The 977 patients’ clinical information is summarized in
Tables 1 and 2. Their median age was 51 but the Chinese
patients were about 10 years younger than the US patients.
Slightly more patients were female (55.5%), especially in China
(59.0% vs 51.4% in United States, P¼ 0.0196). Cumulatively,
more patients harbored nonfunctional tumors (NF) than func-
tional ones but most of the patients with NF were from US
centers. Among the 527 Chinese patients, only 209 had NF
(39.7%), while among the 450 US patients, 345 did (76.7%). Of
the functional tumors, insulinomas were the most common in
both countries, followed by gastrinomas and glucagonomas, and
insulinomas were the predominant tumor type in Chinese
patients (52.2%). In both countries, the vast majority of patients
had sporadic PNETs and 5% had familial syndromes such as
multiple endocrine neoplasia type 1 (MEN1) and von Hippel-
Lindau disease (VHL). Although about 60% of all the primary
tumors located at the body or tail while the remainder at the
head or neck of pancreas, the Chinese PNETs had an even
distribution (49.6% vs 49.0%, Table 1) and 2/3 of US PNETs
were at the body/tail region. At presentation, 32.4% of patients
already had metastasis but the Chinese patients had less metas-
tasis than US counterparts (28.0% vs 38.4%, P¼ 0.0013,
Table 1), mostly due to that the Chinese had larger number
of insulinomas that do not usually metastasize. Most patients
underwent surgical resection of the primary tumor or liver
metastatic lesions but <5% did not due to extensive tumor
burden. The most common site of distant metastases was liver,
followed by bone, lung, and kidney. One Chinese patient with
NF exhibited metastasis to scalp skin.
PNET Grade and Stage
Overall 72.1% of the PNETs had a Ki-67 labeling index
2% and there was a small difference in the percentage of
tumors with Ki-67 labeling index 2% in Chinese and US
patients (69.7% vs 74.8%). As mitotic index was also used to
grade PNETs, tumors withG1 gradewere fewer than thosewith
a Ki-67 labeling index2%. The Chinese and US patients had
similar distribution of G1 (57.7% vs 55.0%), G2 (38.3% vs
41.3%), and G3 (4.0 vs 3.7%) PNETs (Table 1). At presen-
tation, most tumors were at stage I, IIa, or IV in both Chinese
and US patients, and the Chinese patients had more tumors at
stage I or IIa than US patients (61.2% vs 50.3%, P¼ 0.0074,
Table 1).
Analysis of PNET Prognosis
Of the 977 patients, 722 (73.9%) had follow-up data, and
688 of the 722 patients underwent surgical resection. The
median follow-up period was 42 months. Kaplan–Meier
analysis showed that stage, grade, Ki-67 labeling index, and
metastasis were significantly associated with overall survival
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TABLE 1. Summary of Clinicopathological Characteristics of 977 Patients With Pancreatic Neuroendocrine Tumors
Clinicopathological Features of PNETs All Patients China US
Gender n (%), n¼ 971 Male 432 (44.5) 216 (41.0) 216 (48.6)
Female 539 (55.5) 311 (59.0) 228 (51.4)
Male:female 1:1.25 1:1.44 1:1.06
Age at surgery in years, n¼ 977 Median (range) 51 (12–88) 46 (12–85) 56 (12–88)
MeanSD 50.0 14.7 45.7 14.1 55 13.6
Functional type n (%), n¼ 977 Functional 421 (43.1) 318 (60.3) 103 (22.9)
Nonfunctional 554 (56.7) 209 (39.7) 345 (76.7)
Mixed 2 (0.2) 0 (0) 2 (0.4)
PNET subtype n (%), n¼ 977 Insulinoma 328 (33.6) 275 (52.2) 53 (11.8)
Noninsulinoma 649 (66.4) 252 (47.8) 397 (88.2)
Nonfunctional 554 (56.7) 209 (39.7) 345 (76.7)
Gastrinoma 44 (4.5) 21 (4.0) 23 (5.1)
Glucagonoma 28 (2.9) 16 (3.0) 12 (2.7)
VIPoma 15 (1.5) 6 (1.1) 9 (2.0)
Others 8 (0.8) 0 (0) 8 (1.8)
Inheritance n (%), n¼ 974 Sporadic 932 (95.7) 508 (96.9) 424 (94.2)
MEN-1 35 (3.6) 15 (2.9) 20 (4.4)
VHL 5 (0.5) 1 (0.2) 4 (0.9)
Mahvash disease 2 (0.2) 0 (0) 2 (0.4)
Surgical treatment n (%), n¼ 961 Resection 911 (94.8) 474 (90.5) 437 (100)
Nonresection 50 (5.2) 50 (9.5) 0 (0)
Primary tumor site n (%), n¼ 933 Head or neck 396 (42.4) 248 (49.6) 148 (34.2)
Body or tail 530 (56.8) 245 (49.0) 285 (65.8)
Nonpancreas 7 (0.8) 7 (1.4) 0 (0)
Tumor size n (%), n¼ 925 <2 cm 321 (34.7) 184 (36.4) 137 (32.6)
2 cm 604 (65.3) 321 (63.6) 283 (67.4)
<3 cm 502 (54.3) 292 (57.8) 210 (50.0)
3 cm 423 (45.7) 213 (42.2) 210 (50.0)
<4 cm 616 (66.6) 352 (69.7) 264 (62.9)
4 cm 309 (33.4) 153 (30.3) 156 (37.1)
Metastasis n (%), n¼ 874 No 591 (67.6) 365 (72.0) 226 (61.6)
Yes 283 (32.4) 142 (28.0) 141 (38.4)
Lymph node only 69 (7.9) 25 (4.9) 44 (12.0)
Distant 188 (21.5) 111 (21.9) 77 (21.0)
Liver 174 (19.9) 99 (19.5) 75 (20.4)
Bone 11 (1.3) 7 (1.4) 4 (1.1)
Others 9 (1.0) 5 (1.0) 4 (1.1)
Ki-67 staining n (%), n¼ 660 2% 476 (72.1) 244 (69.7) 232 (74.8)
>2% 184 (27.9) 106 (30.3) 78 (25.2)
Grade n (%), n¼ 653 G1 367 (56.2) 173 (57.7) 194 (55.0)
G2 261 (40.0) 115 (38.3) 146 (41.3)
G3 25 (3.8) 12 (4.0) 13 (3.7)
Stage n (%), n¼ 849 I 262 (31.1) 168 (33.4) 94 (27.2)
IIa 215 (25.3) 135 (26.8) 80 (23.1)
IIb 100 (11.8) 52 (10.3) 48 (13.9)
IIIa 10 (1.2) 7 (1.4) 3 (0.9)
IIIb 71 (8.4) 27 (5.4) 44 (12.7)
IV 191 (22.5) 114 (22.7) 77 (22.3)
Follow-up information, n (%) Available 722 (73.9) 288 (54.6) 434 (96.4)
Post-operation, n¼ 688
Follow-up months Median (range) 42 (1–408) 48 (1–302) 36 (1–408)
Overall survival, n (%) 570 (82.8) 229 (88.4) 341 (79.5)
Survival (month) Mean/median 53.2/42.0 56.2/48.0 51.5/36.0
Disease-free survival, n (%) 448 (65.1) 186 (71.8) 262 (61.1)
Alive with disease 119 (17.3) 41 (15.8) 78 (18.2)
Alive with unknown status

3 (0.4) 2 (0.8) 1 (0.2)
Death, n (%) 118 (17.2) 30 (11.6) 88 (20.5)
Dead of PNETs 84 (12.2) 26 (10.0) 58 (13.5)
Dead of unknown cause 34 (4.9) 4 (1.5) 30 (7.0)
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(OS) and disease-free survival (DFS) (Figure 1). Female
patients had slightly better OS but the difference was only a
statistical trend (Suppl. Figure 1, http://links.lww.com/MD/
A703). Functional PNETs exhibited better OS and DFS which
was mainly influenced by the excellent prognosis of insulino-
mas (Suppl. Figure 1, http://links.lww.com/MD/A703). Larger
primary tumor size was significantly associated with worse
prognosis in both Chinese patients and US patients whatever
cutoff value, 2-, 3-, or 4 cm, was used (Figure 2 and Suppl.
Figure 2, http://links.lww.com/MD/A703). Separate Kaplan–
Meier analyses of Chinese and US patients did not reveal
significant differences in the relationships between age, sex,
functionality, metastasis, Ki-67 labeling index, grade, and stage
and OS (Figure 3 and Suppl. Figure 3, http://links.lww.com/
MD/A703) or DFS (Figure 4 and Suppl. Figure 4, http://
links.lww.com/MD/A703), except for that in US patients, Ki-
67 labeling index >2% was not significantly associated with
worse OS (P¼ 0.102, Figure 3F).
Multivariate analysis (Cox models) suggested that higher
grades, more advanced stages and presence of metastasis were
associated with unfavorable OS or DFS (Suppl. Tables 1 and 2,
http://links.lww.com/MD/A703). Primary tumor size <3 cm was
significantly associated with favorable DFS and a statistical trend
of better OS (Suppl. Table 1, http://links.lww.com/MD/A703).
When we correlated the primary tumor size with OS in Chinese
and US cohorts separately, the tumor size was not associated with
OS as the number of patients was smaller in each group (Suppl.
Table 2, http://links.lww.com/MD/A703). The associations of the
above variables with survival were generally similar in Chinese
andUSpatients (Suppl. Table 2, http://links.lww.com/MD/A703).
Comparison of Clinicopathological Features
Between PNET Subgroups of Chinese and US
Patients
As one of the aims of the study was to compare the
clinicopathological characteristics between Chinese and US
PNETs, we further compared different subtypes of Chinese
and US PNETs. Age, tumor size, primary location, grade, and
stage were significantly different between Chinese and US
patients within the same subgroups of PNETs. These data
are summarized in Table 2.
Nonfunctional PNETs (NF)
When the Chinese and US patients were considered as a
single group, a total of 554 patients had NF with more from
United States (n¼ 345, 62.3%) (Tables 1 and 2). The Chinese
NF were significantly larger than United States ones (median
(range) 4 (1–25) vs 3 (0.2–17) cm; meanSD 5.4 3.4 vs
4.0 3.3 cm) and more frequently located in the head/neck
region (54.9% vs 34.8%). The Chinese patients had lower
percentage of G1 (42.4% vs 55.5%) and higher G3 (11.3%
vs 2.7%) tumors than US patients (P¼ 0.001). The Chinese
patients also had lower percentage of stage I (6.4% vs 26.5%)
and higher percentage of stage IV (32.2% vs 20.2%) tumors
than US patients (P¼ 1.5 10–7) (Table 2). The rates of 5-year
OS of Chinese and US patients were similar (91.1% vs 93.3%)
whereas the rate of 10-year OS of Chinese patients was mod-
estly but significantly higher (88.9% vs 73.4%). The rates of
DFS were similar in the Chinese and US patients: 63.6% vs
66.9% at 5 years, and 59.6% vs 61.1% at 10 years (Table 2).
Insulinomas and Noninsulinoma PNETs
As insulinomas are the most common functional PNETs,
they were analyzed as a single group composed of patients from
both countries or separately. A total of 328 patients had
insulinoma with most of them from China (n¼ 275, 83.8%).
Noninsulinoma PNETs were the largest subgroup of PNETs,
including 649 patients with 61.2% of them from the United
States. The median size of insulinomas was the same in Chinese
and US patients (1.5 vs 1.5 cm), in contrast, the median size of
noninsulinoma tumors was 4.0 and 3.0 cm in Chinese and US
patients, respectively (P¼ 4.2 10–8, Table 2). The Chinese
insulinomas relatively more frequently located in the head/neck
region (48.3% vs 26.1%). The Chinese and US insulinomas had
similar distribution of G1 (68.6% vs 58.3%), G2 (31.4% vs
41.7%), and G3 (0% vs 0%) whereas the distribution of grade
was quite different in the noninsulinomas between 2 countries
(P¼ 0.012). In both countries, most insulinomas were at stages I
and II. The Chinese insulinoma patients had a trend of lower
percentage of stages III and IV combined than US patients
(8.4% vs 20.6%, P¼ 0.102) but this was reversed in patients
with noninsulinomas (52.5% vs 37.4%, P¼ 1.3 10–8,
Table 2). The rate of 5- and 10-year OS of Chinese and US
insulinoma patients were similar (96.1% vs 96.0%). The rate of
5-year DFS of the Chinese insulinoma patients was slightly
higher than that of US patients (95.2 % vs 85.6%, P¼ 0.030) but
the rates of 10-year DFS were similar (84.3% vs 85.6%)
(Table 2). In contrast, the rate of 5-year DFS of the Chinese
noninsulinoma patients was significantly lower than that of US
patients (55.4 % vs 69.9%, P¼ 0.003).
DISCUSSION
In this study, we compared the presentation, pathology,
and prognosis of PNETs in Chinese and US patients. To our
knowledge, this is the first multicenter, systemic study of
PNETs in a large cohort of Chinese patients. The use of US
patients as control has allowed us to validate the results of the
study. We demonstrate interesting differences in the presen-
tation of PNETs and gross similarities in the pathology and
prognosis of PNETs among Chinese and US patients.
It may be initially surprising that most Chinese patients had
functional while most US patients had nonfunctional PNET
Clinicopathological Features of PNETs All Patients China US
Without resection, n¼ 29 survival (month) Mean/median 24.3/14.0 24.3/14.0 NA
Alive with disease 24 (82.8) 24 (82.8) NA
Dead of PNETs 4 (13.8) 4 (13.8) NA
Dead of unknown cause 1 (3.4) 1 (3.4) NA
MEN-1¼multiple endocrine neoplasia type 1, PNET¼ pancreatic neuroendocrine tumor, SD¼ standard deviation, VHL¼ von Hippel-Lindau
disease.
Three patients are alive but it is not clear whether they had disease or not.
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FIGURE 1. Kaplan–Meier analysis of overall survival and disease-free survival of patients with PNETs. Left panels are the overall survival
curves and right panels are disease-free survival curves. (A and B) Influence of tumor stage. Blue, green, red, and purples lines represent
patients with stages I, II, III, and IV PNETs, respectively. (C and D) Influence of tumor grade. Blue, green, and red lines represent patients
with G1, G2, and G3 PNETs, respectively. (E and F) Influence of Ki-67 labeling index. Blue and green lines represent patients with PNETs
with Ki-67 labeling index2% and>2%, respectively. (G and H) Influence of metastasis. Blue and green lines represent patients without
and with metastasis, respectively.
Zhu et al Medicine  Volume 95, Number 7, February 2016
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FIGURE 2. Kaplan–Meier analysis of overall survival and disease-free survival of Chinese and US patients in relation to tumor size. (A–F)
Overall survival; (G–L) disease-free survival. Green and blue lines represent patients with tumors<2 and2 cm, respectively (A, B, G, and
H), <3 and 3 cm, respectively (C, D, I, and J), and <4 and 4 cm, respectively (E, F, K, and L).
Medicine  Volume 95, Number 7, February 2016 PNETs at Chinese and US Centers
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FIGURE 3. Comparison of Kaplan–Meier analyses of overall survival of Chinese and US patients. Left panels are the curves of Chinese and
right panels of US patients. (A and B) Influence of tumor stage. Blue, green, red, and purples lines represent patients with stage I, II, III, and
IV PNETs, respectively. (C and D) Influence of tumor grade. Blue, green, and red lines represent patients with G1, G2, and G3 PNETs,
respectively. (E and F) Influence of Ki-67 labeling index. Blue and green lines represent patients with PNETs with Ki-67 labeling index2%
and >2%, respectively. (G and H) Influence of metastasis. Blue and green lines represent patients without and with metastasis,
respectively.
Zhu et al Medicine  Volume 95, Number 7, February 2016
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FIGURE 4. Comparison of Kaplan–Meier analyses of disease-free survival of Chinese and US patients. Left panels are the curves of Chinese
and right panels of US patients. (A and B) Influence of tumor stage. Blue, green, red, and purples lines represent patients with stage I, II, III,
and IV PNETs, respectively. (C and D) Influence of tumor grade. Blue, green, and red lines represent patients with G1, G2, and G3 PNETs,
respectively. (E and F) Influence of Ki-67 labeling index. Blue and green lines represent patients with PNETs with Ki-67 labeling index2%
and >2%, respectively. (G and H) Influence of metastasis. Blue and green lines represent patients without and with metastasis,
respectively.
Medicine  Volume 95, Number 7, February 2016 PNETs at Chinese and US Centers
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(NF) but evolution of the epidemiology of NF in the United
States suggests that the smaller NF case numbers in Chinese
patients may be due to a detection bias. NF used to be con-
sidered rare in US populations as well but has become more
common than functional tumors in recent years. At Mayo
Clinic, the percentage of NF increases from 15% between
1960 and 1978 to 53% between 1985 and 1993.17,18 Similarly,
at MD Anderson Cancer Center, the percentage of NF increases
from 44% between 1950 and 1987 to 91% between 2001 and
2009.19,20 The same increase of the frequency of NF is also
observed at Massachusetts General Hospital.21 The increase
of the frequency of NF is most likely due to early detection
of NF by sensitive imaging modalities such as CT and MRI
before the tumor causes clear symptoms. In China where
sophisticated imaging is currently probably not as widely used
as in the United States,22,23 early detection of NF is thus
less likely, explaining its apparent lower relative incidence
than that of functional tumors. On the other hand, we cannot
rule out that NF is genuinely uncommon in China. Future
epidemiological studies of PNETs in Chinese patients would
clarify this issue.
Although most Chinese patients with PNETs were middle-
aged, like the US patients, the apparent younger age of pres-
entation of insulinomas and NF in Chinese patients is intriguing.
As there are no known environmental or behavioral factors
contributing to PNETs pathogenesis,1–5 it is presumptive to
discuss factors that make Chinese PNET patients present at
younger ages. However, there could be several potential under-
lying causes of this phenomenon. The Chinese patients may be
genetically more susceptible to PNETs, thus presenting at a
younger age. Since more Chinese NFs locate in pancreatic head
or neck where the tumors tend to cause symptoms earlier than
tumors at pancreatic body or tail, Chinese NF patients may thus
present at an earlier age. Moreover, the tumor size of NF in
Chinese patients was relatively larger than that of US patients,
which also results in symptoms at earlier stage of the tumor.
Another possible explanation of the younger age of Chinese
patients with PNETs is that the life expectancy of Chinese
people (74.8 years) is about 3 years shorter than that of US
people (78.2 years), so that older Chinese patients who would
otherwise be diagnosed with PNETs may die of other causes
before being diagnosed. Interestingly, the age of patients with
PNETs in the United States is getting older since 1960s. For
example, at MD Anderson Cancer Center, the mean age of
patients with PNETs used to be younger as well but grew from
49 years between 1950 and 1987 to 58 years between 2001 and
2009.19,20 The higher female to male ratio in Chinese PNET
patients (1.44:1) is different from the equal sex distribution in
US patients but similar to the sex ratio (female to male: 1.6:1)
in Japanese patients.6 These findings suggested that PNETs in
Eastern Asian countries might be different from those in the
United States and further studies are needed to address the
underlying causes of the different sex ratio.
The larger size of the Chinese NF is also interesting. The
Chinese NF may be biologically prone to cell proliferation or to
allowmore rapid tumor expansion. This hypothesis is supported
by our present finding that almost twice as much Chinese NF
had Ki-67 >2%, compared with US NF (43.8% vs 23.5%). In
addition, there might be unknown environmental factors present
in China to promote PNET growth. Alternatively, the size
difference may be a result of symptom-based tumor detection.
As small NFs are usually asymptomatic, especially when they
are located in the body/tail of pancreas, they will remain
undetected until incidentally identified by imaging.1–5 The
symptom-based diagnostic workup thus mostly identifies larger
tumors and tumors at the head/neck of pancreas, which are more
common in the Chinese patients. Before the advent of frequent
imaging procedures in the United States, NFs were also larger
than those seen in contemporary practice. At Massachusetts
General Hospital, for example, the average size of NFs
decreases from 5.6 cm between 1977 and 1999 to 4.1 cm
between 2000 and 2005.21
Despite the several differences in the presentation of
PNETs in Chinese and US patients, pathological classification
of PNETs by the same grading and staging criteria appears to be
feasible and validated. The Chinese NFs that tend to be larger
(thus suggesting higher proliferation rate) are indeed classified
into higher grades and more advanced stages while the Chinese
insulinomas which are very similar to the US counterparts are
appropriately classified into lower grades and earlier stages.
Tumor grade distribution shown in our study is similar between
Chinese and US patients, and is close to those from previous
larger studies in Europe and United States, especially a large
multicenter European study,10,24–27 and a small study in Ja-
pan,16 suggesting that in academic centers, most PNETs present
as G1, followed by G2, and remotely by G3 grade. Survival data
stratified by the WHO/ENETS grades are also consistent with
data from validation studies in European and other US cen-
ters,24–27 supporting the validity of WHO/ENETS grading in
Asian countries and for Asian patients. Likewise, the distri-
bution of tumor stage in our study is also approximately similar
between Chinese and US patients, and the distributions of
Stages I and IV tumors are very similar to those reported in
a large multicenter study.10 In addition, the survival data
stratified by ENETS TNM staging are similar between Chinese
and US patients, and are largely close to those from previous
studies using similar or other TNM-based staging sys-
tems.25,26,28–30 Our study thus indicates that the ENETS grad-
ing and staging criteria can be universally applied to PNETs in
most countries.
Themostly similar prognosis of PNETs in Chinese andUS
patients suggests that the prognosis of PNETs is largely a
function of tumor grade and stage, so long as surgical resection
of primary and metastatic tumors and locoregional therapy of
liver metastatic tumor, the 2 common treatments invariably
used whenever feasible in both countries. It has been suggested
that somatostatin analogs may improve the survival of patients
with small bowel carcinoids and PNETs.31 Although the 7
Chinese centers are among the best academic hospitals in
China, the use of somatostatin analogs and other medications
is often limited by patients’ inability to afford them, thus much
fewer Chinese patients received these medications but unfor-
tunately the accurate data are not available to us. Our study thus
cannot reliably address the survival benefits of somatostatin
analogs.
Our study has several limitations. As described earlier, we
did not have data on detailed systemic treatment on most
Chinese patients. This is a retrospective study with the intrinsic
shortcomings of a retrospective study. The Chinese and US
patient populations contain uneven proportions of functional
tumors and NF, making the comparison of overall PNET
prognosis less feasible. We used survival, a more definitive
measure of prognosis, but did not have data on patients’
symptoms and quality of life, which are both important
measures of prognosis. These limitations, however, do not
diminish the value of our main findings.
In summary, this multicenter, cross-Pacific study of
nearly 1000 patients with PNETs demonstrates that the
Zhu et al Medicine  Volume 95, Number 7, February 2016
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contemporary Chinese patients in general are younger, have
relatively fewer nonfunctional tumors, and larger tumors than
US patients. Tumor grades and stages are also different
in subgroups of PNETs between the 2 countries. PNET
prognosis is similarly associated with tumor grade, stage, metas-
tasis, and primary tumor size. Thus, PNETs in Chinese and US
patients likely follow a similar natural history and the ENETS
grading and staging criteria are validated in Chinese patients. The
same criteria can probably be used in Asian patients at large.
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